Amarin Corp Plc (AMRN)

[AVII77]

I really don't know.

I would like to see it stopped for efficacy. That would be a positive for humanity. What effect it would have on R-IT is questionable. It would add support to the inflammation hypothesis. But as JL notes the MOA of attacking inflammation is different.

If it failed.... well, that sucks for humanity. But, if R-IT succeeds we wouldn't have cheap competition.

If you're watching the talk, I thought the slide discussing the reduction in CVD risk in RA patients was interesting (and very fairly presented .... taking care to emphasize the data are from non-controlled observational studies).

But that talk laid out a very good case for conducting the trial. Surprised it enrolled so poorly.

The slides discussing JUPITER were also interesting.

I'd be curious to hear your view (or anyone's) after watching it.